[1]杨会勇,黄思彬,马丽浩,等.ICIs时代晚期肾细胞癌幸存者的后续原发性癌症谱分析[J].华侨大学学报(自然科学版),2025,46(6):685-693.[doi:10.11830/ISSN.1000-5013.202504039]
　YANG Huiyong,HUANG Sibin,MA Lihao,et al.Analysis of Subsequent Primary Cancer Spectrum in Survivors of Advanced Renal Cell Carcinoma in ICIs Era[J].Journal of Huaqiao University(Natural Science),2025,46(6):685-693.[doi:10.11830/ISSN.1000-5013.202504039]
点击复制

ICIs时代晚期肾细胞癌幸存者的后续原发性癌症谱分析()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
第46卷
期数:
2025年第6期
页码:
685-693
栏目:
出版日期:
2025-11-20

文章信息/Info

Title:
Analysis of Subsequent Primary Cancer Spectrum in Survivors of Advanced Renal Cell Carcinoma in ICIs Era
文章编号:
1000-5013(2025)06-0685-09
作者:
杨会勇;  黄思彬;  马丽浩;  苏兴豪;  蔡亚设;  史佳可;  刘卓晟;  狄彦君;  刁勇;  吴循循
华侨大学 医学院, 福建 泉州 362021
Author(s):
YANG Huiyong;  HUANG Sibin;  MA Lihao;  SU Xinghao;  CAI Yashe;  SHI Jiake;  LIU Zhuosheng;  DI Yanjun;  DIAO Yong;  WU Xunxun
School of Medicine, Huaqiao University, Quanzhou, 362021, China
关键词:
肾细胞癌;  后续原发癌;  免疫检查点抑制剂;  标准化发病率
Keywords:
renal cell carcinoma;  subsequent primary cancer;  immune checkpoint inhibitor;  standardized incidence rate
分类号:
R73.31;R737.11;R730.1
DOI:
10.11830/ISSN.1000-5013.202504039
文献标志码:
A
摘要:
为了评估免疫检查点抑制剂(ICIs)时代(2015年11月-2021年12月)晚期肾细胞癌(RCC)幸存者的后续原发性癌症(SPCs)风险特征及影响因素,基于SEER数据库纳入的873例晚期RCC患者,计算标准化发病率比(RSi )和超额风险,按性别及COVID-19流行前后分层进行分析。结果表明:晚期肾细胞癌患者面临50%更高的实体瘤风险((95%CI:1.40~1.61),每年超额风险为每10 000人有63.89人);女性泌尿系统(膀胱,女性RSi =2.39,男性RSi =1.56)和呼吸系统(肺及支气管癌,女性RSi =1.57,男性RSi =1.11)风险较高,而男性甲状腺(男性RSi =6.17,女性RSi =5.41)风险较高;疫情后,肺及支气管癌显著性降低(RSi =1.12,P>0.05),表明诊断延迟,而甲状腺癌(RSi =4.58)仍高风险。
Abstract:
To assess the risk characteristics and influencing factors of subsequent primary cancers(SPCs)in survivors of advanced renal cell carcinoma(RCC)in the era of immune checkpoint inhibitors(ICIs)(November 2015-December 2021), standardized incidence ratios(RSi)and excess risks were calculated based on the SEER database, and 873 patients with advanced RCC were included. Analysis was performed stratified by gender and period before and after the COVID-19 epidemic. The results showed that patients with advanced RCC faced 50% higher solid tumors risks((95%CI:1.40-1.61), and excess risks were 63.89 people per 10 000 people in every year. The risks were higher in the female urinary system(bladder,RSi=2.39 in women,RSi=1.56 in men)and respiratory system(lung and bronchial cancer,RSi=1.57 in women,RSi=1.11 in men), however, the risks of the thyroid gland in males were higher(RSi=6.17 in men, RSi=5.41 in women). After the epidemic, lung and bronchial cancers decreased significantly(RSi=1.12, P >0.05), indicating delayed diagnosis, while thyroid cancer remained at high risk(RSi=4.58).

参考文献/References:

[1] BARATA P C,RINI B I.Treatment of renal cell carcinoma: Current status and future directions[J].CA: A Cancer Journal for Clinicians,2017,67(6):507-524.DOI:10.3322/caac.21411.
[2] BAHADORAM S,DAVOODI M,HASSANZADEH S,et al.Renal cell carcinoma: An overview of the epidemiology, diagnosis,and treatment[J].Giornale Italiano di Nefrologia,2022,39(3):1-3.
[3] SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer statistics, 2022[J].CA: A Cancer Journal for Clinicians,2022,72(1):7-33.DOI:10.3322/caac.21708.
[4] CHOW W H,DONG L M,DEVESA S S.Epidemiology and risk factors for kidney cancer[J].Nature Reviews Urology,2010,7(5):245-257.DOI:10.1038/nrurol.2010.46.
[5] PDQ ADULT TREATMENT EDITORIAL BOARD.Renal cell cancer treatment(PDQ): Patient version[R].Bethesda MD:National Cancer Institute,2002.
[6] SURVEILLANCE RESEARCH PROGRAM,NATIONAL CANCER INSTITUTE.SEER Cancer statistics animator[EB/OL].(2020-05-12)[2025-03-05] .https://seer.cancer.gov/canstat/animator/#v3=0E0000.4FF0000.20.30;o=0032033;v2=0E0000.40000FF.20.17;y=2015f;v1=0E0000.4000000.20.0.
[7] HASANOV E,GAO J,TANNIR N M.The immunotherapy revolution in kidney cancer treatment: Scientific rationale and first-generation results[J].The Cancer Journal: The Journal of Principles & Practice of Oncology,2020,26(5):419-431.DOI:10.1097/ppo.0000000000000471.
[8] BRAHMER J R,DRAKE C G,WOLLNER I,et al.Phase Ⅰ study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates[J].Journal of Clinical Oncology,2010,28(19):3167-3175.DOI:10.1200/jco.2009.26.7609.
[9] MOTZER R J,RINI B I,MCDERMOTT D F,et al.Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase Ⅱ trial[J].Journal of Clinical Oncology,2015,33(13):1430-1437.DOI:10.1200/jco.2014.59.0703.
[10] TANNIR N M,ALBIG?S L,MCDERMOTT D F,et al.Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase Ⅲ checkmate 214 trial[J].Annals of Oncology,2024,35(11):1026-1038.DOI:10.1016/j.annonc.2024.07.727.
[11] PLIMACK E R,POWLES T,STUS V,et al.Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 keynote-426 study[J].European Urology,2023,84(5):449-454.DOI:10.1016/j.eururo.2023.06.006.
[12] POWLES T,ALBIGES L,BEX A,et al.Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J].Annals of Oncology,2024,35(8):692-706.DOI:10.1016/j.annonc.2024.05.537.
[13] LALANI A A,BAIOUNY Z,FARAH S,et al.Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma(RCC)[J].AMA Oncology,2021,7(5):773-775.DOI:10.1001/jamaoncol.2021.0019.
[14] BENGTSEN M B,FARKAS D K,S?RENSEN H T,et al.Renal cell carcinoma and risk of second primary cancer: A danish nationwide cohort study[J].Cancer Medicine,2024,13(11):e7237.DOI:10.1002/cam4.7237.
[15] LIU H,HEMMINKI K,SUNDQUIST J.Renal cell carcinoma as first and second primary cancer: Etiological clues from the Swedish Family-Cancer Database[J].The Journal of Urology,2011,185(6):2045-2049.DOI:10.1016/j.juro.2011.02.001.
[16] DENG Weiye,WANG Yifan,LIU Xiangyu,et al.Assessment of trends in second primary cancers in patients with metastatic melanoma from 2005 to 2016[J].JAMA Network Open,2020,3(12):e2028627.DOI:10.1001/jamanetworkopen.2020.28627.
[17] HEUDEL P E,DE MONTFORT A,DEBIEUVRE D,et al.Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors[J].Lung Cancer,2023,182:107280.DOI:10.1016/j.lungcan.2023.107280.
[18] WANG Xinyu,ZENG Meiyuan,JU Xueming,et al.Correlation between second and first primary cancer: Systematic review and meta-analysis of 9 million cancer patients[J].British Journal of Surgery,2024,111(1):znad377.DOI:10.1093/bjs/znad377.
[19] RABBANI F,GRIMALDI G,RUSSO P.Multiple primary malignancies in renal cell carcinoma[J].The Journal of Urology,1998,160(4):1255-1259.
[20] BEISLAND C,TALLERAAS O,BAKKE A,et al.Multiple primary malignancies in patients with renal cell carcinoma: A national population-based cohort study[J].BJU International,2006,97(4):698-702.DOI:10.1111/j.1464-410X.2006.06004.x.
[21] MOUBARAK S,MERHEB D,BASBOUS L,et al.COVID-19 and lung cancer: Update on the latest screening,diagnosis,management and challenges[J].Journal of International Medical Research,2022,50(9):3000605221125047.DOI:10.1177/03000605221125047.
[22] TARAWNEH T S,MACK E K M,FAORO C,et al.Diagnostic and therapeutic delays in lung cancer during the COVID-19 pandemic: A single center experience at a German Cancer Center[J].BMC Pulmonary Medicine,2024,24(1):320.DOI:10.1186/s12890-024-03082-x.
[23] WANG Yubo,JIANG Yining,BAI Yang,et al.Do cancer survivors have an increased risk of developing subsequent cancer?: A population-based study[J].Journal of Translational Medicine,2025,23(1):355.DOI:10.1186/s12967-025-06379-5.
[24] FRITZ A P C,JACK A,SHANMUGARATNAM K,et al.International classification of diseases for oncology[M].Geneva:World Health Organization,2000.
[25] SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS(SEER)PROGRAM.SEER summary staging manual 2000 [M].Bethesda,MD:National Cancer Institute,2000.
[26] AMERICAN CANCER SOCIETY.Kidney cancer stages[EB/OL].(2024-05-03)[2025-03-05] .https://amp.cancer.org/cancer/types/kidney-cancer/detection-diagnosis-staging/staging.html.
[27] WORKING GROUP REPORT.International rules for multiple primary cancers(ICD-0 third edition)[J].European Journal of Cancer Prevention,2005,14(4):307-308.DOI:10.1097/00008469-200508000-00002.
[28] TRAVIS L B.The epidemiology of second primary cancers[J].Cancer Epidemiology, Biomarkers & Prevention,2006,15(11):2020-2026.DOI:10.1158/1055-9965.Epi-06-0414.
[29] REZAEI S J,EID E,TANG J Y,et al.Incidence of nonkeratinocyte skin cancer after breast cancer radiation therapy[J].JAMA Network Open,2024,7(3):e241632.DOI:10.1001/jamanetworkopen.2024.1632.
[30] BECHER H,WINKLER V.Estimating the standardized incidence ratio(SIR)with incomplete follow-up data[J].BMC Medical Research Methodology,2017,17(1):55.DOI:10.1186/s12874-017-0335-3.
[31] YANG Zihui,LIU Xinyu,YANG Xi,et al.Second primary malignancies after ovarian cancer: A SEER-based analysis(1975-2016)[J].Taiwan Journal of Obstetrics and Gynecology,2022,61(1):80-85.DOI:10.1016/j.tjog.2021.11.015.
[32] CHAKRABORTY S,TARANTOLO S R,BATRA S K,et al.Incidence and prognostic significance of second primary cancers in renal cell carcinoma[J].American Journal of Clinical Oncology,2013,36(2):132-142.DOI:10.1097/COC.0b013e3182438ddf.
[33] THOMPSON R H,LEIBOVICH B C,CHEVILLE J C,et al.Second primary malignancies associated with renal cell carcinoma histological subtypes[J].The Journal of Urology,2006,176(3):900-903.DOI:10.1016/j.juro.2006.04.080.
[34] TURKI? M,ZNAOR A,NOVOSEL I,et al.Second primary malignant tumors in patients with primary renal cell carcinoma[J].Acta Medica Croatica,2005,59(2):91-95.
[35] RONCKERS C M,MCCARRON P,RON E.Thyroid cancer and multiple primary tumors in the SEER cancer registries[J].International Journal of Cancer,2005,117(2):281-288.DOI:10.1002/ijc.21064.
[36] BERTHE E,HENRY-AMAR M,MICHELS J J,et al.Risk of second primary cancer following differentiated thyroid cancer[J].European Journal of Nuclear Medicine and Molecular Imaging,2004,31(5):685-691.DOI:10.1007/s00259-003-1448-y.
[37] GUPTA T,ANTANAVICIUTE A,HYUN-JUNG LEE C,et al.Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis[J].Cancer Cell,2024,42(5):797-814.DOI:10.1016/j.ccell.2024.04.010.
[38] KARAVITI D,KANI E R,KARAVITI E,et al.Thyroid disorders induced by immune checkpoint inhibitors[J].Endocrine,2024,85(1):67-79.DOI:10.1007/s12020-024-03718-2.
[39] HAH Y S,KOO K C.Immunology and immunotherapeutic approaches for advanced renal cell carcinoma: A Comprehensive Review[J].International Journal of Molecular Sciences,2021,22(9):4452.DOI:10.3390/ijms22094452.
[40] VALERO C,LEE M,HOEN D,et al.Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase[J].JAMA Oncology,2021,7(5):739-743.DOI:10.1001/jamaoncol.2020.7684.
[41] GOTO T,MIYAMOTO H.The role of estrogen receptors in urothelial cancer[J].Frontiers in Endocrinology,2021,12:643870.DOI:10.3389/fendo.2021.643870.
[42] IDE H,INOUE S,MIYAMOTO H.Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies[J].Public Library of Science One,2017,12(3):e0174746.DOI:10.1371/journal.pone.0174746.
[43] LIN Gen,FAN Xirong,ZHU Weifeng,et al.Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer[J].Oncotarget,2017,8(48):83986-83994.DOI:10.18632/oncotarget.20233.
[44] FU Fangqiu,DENG Chaoqiang,SUN Wenrui,et al.Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer[J].Respiratory Research,2022,23(1):302.DOI:10.1186/s12931-022-02201-8.
[45] ROTA M,POSSENTI I,VALSASSINA V,et al.Dose-response association between cigarette smoking and gastric cancer risk: A systematic review and meta-analysis[J].Gastric Cancer,2024,27(2):197-209.DOI:10.1007/s10120-023-01459-1.
[46] ZHOU Xuan,XIAO Qian,JIANG Fangyuan,et al.Dissecting the pathogenic effects of smoking and its hallmarks in blood DNA methylation on colorectal cancer risk[J].British Journal of Cancer,2023,129(8):1306-1313.DOI:10.1038/s41416-023-02397-6.
[47] MYNARD N,SAXENA A,MAVRACICK A,et al.Lung cancer stage shift as a result of COVID-19 lockdowns in New York City, a brief report[J].Clinical Lung Cancer,2022,23(3):e238-e242.DOI:10.1016/j.cllc.2021.08.010.
[48] MORRIS E J A,GOLDACRE R,SPATA E,et al.Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: A population-based study[J].The Lancet Gastroenterology & Hepatology,2021,6(3):199-208.DOI:10.1016/s2468-1253(21)00005-4.
[49] HEUDEL P,CHABAUD S,PEROL D,et al.Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer[J].ESMO Open: Cancer Horizons,2021,6(1):100044.DOI:10.1016/j.esmoop.2020.100044.

备注/Memo

备注/Memo:
收稿日期: 2025-04-22
通信作者: 杨会勇(1978-),男,副教授,博士,主要从事重大疾病早期预警系统及检测平台构建的研究。E-mail:shyhy@hqu.edu.cn。
基金项目: 福建省自然科学基金资助项目(2022J05062); 福建省厦门自然科学基金资助项目(3502Z20227041); 华侨大学中青年教师科技创项目(ZQN-PY319); 中央高校基本科研业务费资助项目(21BS126)https://hdxb.hqu.
更新日期/Last Update: 2025-11-20